Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
12,388 stopped studies mapped to Malignant Neoplasm and descendants · 89% state a reason
Over the 12,388 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 21, 2007 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT00401401 | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck Cancer | Phase 1 / Phase 2 | terminated | Nov 20, 2006 | Genmab | MTD was established and patients completed 16 months safety f-up and response assessments. It is… | Safety / toxicity |
| NCT00555867 | Patient's Anastrozole Compliance to Therapy Programme(PACT) | — | terminated | Nov 9, 2007 | AstraZeneca | High drop-out rate leads to the conclusion: not enough data will be available to perform proper… | Other (stated, no rule matched) |
| NCT00432419 | Therapeutic Intensification of HIV-associated Non-Hodgkin's Lymphoma by Peripheral Blood… | Phase 1 / Phase 2 | terminated | Feb 7, 2007 | French National Agency for Research on AIDS and Viral Hepatitis | only one patient enrolled | Enrollment / accrual |
| NCT01106235 | Therapeutic Autologous Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating… | Phase 1 | terminated | Apr 19, 2010 | Fred Hutchinson Cancer Center | not stated | Not stated |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 27, 2011 | Pfizer | Business/Operational issues | Sponsor / business decision |
| NCT00473551 | Anti-Third Party T Lymphocytes With Nonmyeloablative Stem Cell Transplantation for… | Phase 1 | terminated | May 15, 2007 | M.D. Anderson Cancer Center | Terminated due to slow accrual. | Enrollment / accrual |
| NCT00533169 | ZD6474 Alone and in Combination With Retinoic Acid in Pediatric Neuroblastoma | Phase 1 | terminated | Sep 21, 2007 | M.D. Anderson Cancer Center | Lack of enrollment. | Enrollment / accrual |
| NCT00554775 | WBRT & Erlotinib in Advanced NSCLC and Brain Metastases(TACTIC) | Phase 2 | terminated | Nov 7, 2007 | University College, London | IDMC made a recommendation to stop the trial as the target for continuing to the 2nd phase was not… | Other (stated, no rule matched) |
| NCT01229605 | Cyclophosphamide and Docetaxel Every 3 Weeks as Neoadjuvant Therapy in Locally Advanced… | Phase 2 | withdrawn | Oct 28, 2010 | Tufts Medical Center | Study was not a good fit for the patient population seen at this hospital. | Other (stated, no rule matched) |
| NCT01313390 | Everolimus and Docetaxel in Treating Patients With Recurrent, Locally Advanced, or…(DORA) | Phase 1 / Phase 2 | terminated | Mar 11, 2011 | University College, London | Lack of recruitment | Enrollment / accrual |
| NCT00122252 | Biological Imaging for Optimising Clinical Target Volume (CTV) and Gross Tumour Volume… | — | terminated | Jul 22, 2005 | Alberta Health services | Study abandoned. | Other (stated, no rule matched) |
| NCT00790452 | Aspirin Prophylaxis for Venous Thromboembolism in Glioblastoma | Phase 2 | terminated | Nov 13, 2008 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT01100489 | Breast-Conserving Surgery Followed by Radiation Therapy With MRI-Detected Stage I or… | Phase 2 | withdrawn | Apr 9, 2010 | Case Comprehensive Cancer Center | No accrual | Enrollment / accrual |
| NCT00410865 | Wild Type p53 Adenovirus for Oral Premalignancies | Phase 1 | terminated | Dec 13, 2006 | M.D. Anderson Cancer Center | Sponsor withdrawl prior to study completion. | Other (stated, no rule matched) |
| NCT00895297 | Efficacy and Safety Study of Dasatinib in Patients With Chronic Myeloid Leukemia(Dasatinib) | Phase 2 | terminated | May 8, 2009 | European Society for Blood and Marrow Transplantation | Slow recruitment. No safety concerns during this study. | Safety / toxicity |
| NCT00460551 | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer | Phase 2 | terminated | Apr 16, 2007 | Genmab | Due to considerations regarding the appropriate therapeutic regimen for these patients. | Other (stated, no rule matched) |
| NCT00860249 | Outreach for Patients That Are Newly Eligible for Colorectal Cancer Screening(UPQUAL) | N/A | terminated | Mar 12, 2009 | Northwestern University | Lack of sufficient participants meeting the eligibility criteria to complete study in proposed and… | Other (stated, no rule matched) |
| NCT01127542 | RESPeCT: Revlimid Early Stage Poor Prognosis Chronic Lymphocytic Leukaemia (CLL) Trial(RESPeCT) | Phase 2 | terminated | May 21, 2010 | The Christie NHS Foundation Trust | Potential safety issue of second primary malignancies in patients treated with lenalidomide. | Safety / toxicity |
| NCT01175291 | FOLFOX/Bevacizumab +/- MK-0646 in Metastatic Colorectal Cancer | Phase 2 | withdrawn | Aug 4, 2010 | H. Lee Moffitt Cancer Center and Research Institute | treatment deemed ineffective so accrual was closed | Enrollment / accrual |
| NCT00593008 | Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic… | Phase 1 | terminated | Jan 14, 2008 | Massachusetts General Hospital | not stated | Not stated |
| NCT01153113 | Human Telomerase Reverse Transcriptase Messenger RNA (hTERT mRNA) Transfected Dendritic… | Phase 1 / Phase 2 | withdrawn | Jun 29, 2010 | University of Florida | IND has been withdrawn and the study is closed. | Other (stated, no rule matched) |
| NCT01006902 | Outcomes of Oncology Therapy in the Elderly: Trajectory of Functional Decline and… | — | terminated | Nov 3, 2009 | University of Vermont | Insufficient recruitment | Enrollment / accrual |
| NCT00418574 | Efficacy Multicentre Trial of ImmunoTherapy Vaccination With Abagovomab to Treat Ovarian…(MIMOSA) | Phase 2 / Phase 3 | terminated | Jan 5, 2007 | Menarini Group | No benefit on primary end point (RFS); no rationale to collect survival data | Other (stated, no rule matched) |
| NCT00400764 | A Study of Dulanermin in Combination With Rituximab in Subjects With Follicular and Other… | Phase 1 / Phase 2 | terminated | Nov 17, 2006 | Genentech, Inc. | not stated | Not stated |
| NCT00937300 | T-cell Based Immunotherapy for Head and Neck Cancer | Phase 1 | withdrawn | Jul 13, 2009 | Inge Marie Svane | The patients eligible for this trial do not exist anymore due to change in procedures. | Other (stated, no rule matched) |
| NCT00587015 | A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Patients With Non-Hodgkin's… | Phase 1 | terminated | Jan 7, 2008 | MedImmune LLC | Due to a lack of IP supply and then terminated because they were combined into one new study with… | Drug supply |
| NCT01242943 | Radioimmunotherapy With 131I-L19SIP in Patients With Cancer | Phase 1 / Phase 2 | terminated | Nov 17, 2010 | Philogen S.p.A. | With the determination of the RD and a well established understanding of the safety and… | Safety / toxicity |
| NCT00803374 | Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma | Phase 1 | withdrawn | Dec 5, 2008 | Bristol-Myers Squibb | not stated | Not stated |
| NCT00796055 | Study of MEDI-547 to Evaluate the Safety, Tolerability, and Biologic Activity of IV…(MEDI-547) | Phase 1 | terminated | Nov 24, 2008 | MedImmune LLC | MI-CP177 study closed per sponsor decision. | Sponsor / business decision |
| NCT00505921 | Autologous and Allogenic Transplantation With Campath-1H for T-Cell Lymphoma | Phase 2 | terminated | Jul 25, 2007 | M.D. Anderson Cancer Center | Slow Accrual. | Enrollment / accrual |
| NCT00169221 | Post-operative Radiotherapy With Cisplatin Alone or in Combination With Iressa in Upper… | Phase 2 | terminated | Sep 15, 2005 | Groupe Oncologie Radiotherapie Tete et Cou | Toxicity in an independent study IMEX. The trial was subsequently terminated (54 pts instead of… | Safety / toxicity |
| NCT00926107 | Study of the mTOR Inhibitor Temsirolimus (CCI-779) to Treat Ovarian Cancer With CA125… | Phase 2 | terminated | Jun 23, 2009 | Hellenic Cooperative Oncology Group | The study ended prematurely due to the low accrual rate (24% of the expected accrual rate) in the… | Enrollment / accrual |
| NCT01245582 | Oxaliplatin and Capecitabine on Top of Sorafenib Versus Sorafenib Alone in Advanced…(SECOX) | Phase 3 | withdrawn | Nov 22, 2010 | Sanofi | not stated | Not stated |
| NCT00925405 | Breast Magnetic Resonance Imaging (MRI) Screening After Mantle Radiation Therapy | — | terminated | Jun 22, 2009 | M.D. Anderson Cancer Center | Low accrual | Enrollment / accrual |
| NCT00519090 | Nilotinib vs Imatinib in Adult Patients With Philadelphia (Ph+) Chronic Myelogenous…(ENEST) | Phase 3 | terminated | Aug 21, 2007 | Novartis Pharmaceuticals | This study was terminated due to limited enrollment. | Enrollment / accrual |
| NCT00918931 | Obatoclax for Systemic Mastocytosis | Phase 2 | terminated | Jun 11, 2009 | M.D. Anderson Cancer Center | not stated | Not stated |
| NCT00184288 | Proton MR Spectroscopy of Brain Metastases in Evaluation of Treatment Response. | — | withdrawn | Sep 16, 2005 | Norwegian University of Science and Technology | no patients recruited | Enrollment / accrual |
| NCT00779311 | A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for… | Phase 1 | terminated | Oct 24, 2008 | Accelerated Community Oncology Research Network | Dose limiting toxicity at the lowest planned dose level. | Safety / toxicity |
| NCT00028483 | Monoclonal Antibody Therapy and Docetaxel in Treating Women With Metastatic or Recurrent… | Phase 2 | terminated | Jun 27, 2003 | Seagen Inc. | not stated | Not stated |
| NCT00060710 | CP-461 in the Treatment of Patients With Advanced Melanoma | Phase 2 | terminated | May 13, 2003 | Astellas Pharma Inc | not stated | Not stated |
| NCT00225290 | Phase III Trial of Oral Thalidomide in Advanced Hepatocellular Carcinoma With Poor Liver… | Phase 3 | terminated | Sep 23, 2005 | TTY Biopharm | slowly recruitment rate | Enrollment / accrual |
| NCT00747825 | Phase I Safety and Dosimetry Study in Patients With Confirmed Metastatic Melanoma | Phase 1 | terminated | Sep 5, 2008 | Molecular Insight Pharmaceuticals, Inc. | not stated | Not stated |
| NCT01449357 | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosine Kinase… | Phase 2 | withdrawn | Oct 10, 2011 | Genmab | Trial never initiated | Other (stated, no rule matched) |
| NCT00679874 | Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular…(Cardiotox) | — | terminated | May 19, 2008 | University of Calgary | No subjects indentifiable | Other (stated, no rule matched) |
| NCT01300702 | Neuropathic in the Acute Post Operative Phase | — | terminated | Feb 23, 2011 | Rigshospitalet, Denmark | recruitment problems | Enrollment / accrual |
| NCT01011998 | A Study of Imatinib and Valproic Acid in Patients With Chronic Myelogenous Leukemia (CML) | Phase 2 | withdrawn | Nov 11, 2009 | New Mexico Cancer Research Alliance | Withdrawn due to lack of accrual per Center DSMP, with PI concurrence | Enrollment / accrual |
| NCT00515086 | Study of Everolimus (RAD001) in Patients With Recurrent Glioblastoma Multiforme (GBM) | Phase 2 | terminated | Aug 13, 2007 | Novartis Pharmaceuticals | Early termination due to slow enrollment and protocol-defined stopping rule. | Enrollment / accrual |
| NCT00712062 | Study of Pemetrexed to Treat Recurrent or Progressive Primary Central Nervous System… | Phase 2 | withdrawn | Jul 9, 2008 | University of Florida | Lack of accrual | Enrollment / accrual |
| NCT00452387 | Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone… | Phase 2 | terminated | Mar 27, 2007 | Accelerated Community Oncology Research Network | Early stopping rule | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Dec 26, 2011source: clinicaltrials